Technical Analysis for BCEL - Atreca, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.59% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.59% | |
| Upper Bollinger Band Touch | Strength | 0.59% | |
| 20 DMA Support | Bullish | 6.88% | |
| Bollinger Band Squeeze | Range Contraction | 6.88% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 6.88% |
| Alert | Time |
|---|---|
| Up 5% | about 8 hours ago |
| 60 Minute Opening Range Breakout | about 9 hours ago |
| 10 DMA Support | about 11 hours ago |
| Rose Above Upper Bollinger Band | about 11 hours ago |
| Up 3% | about 11 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca’s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Immunology Solid Tumors Immune System Antibodies Tumor Cancer Immunotherapy Monoclonal Antibody Drug Discovery Antibody Glycoproteins Immune Response Immunotherapeutics Agenus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Immunology Solid Tumors Immune System Antibodies Tumor Cancer Immunotherapy Monoclonal Antibody Drug Discovery Antibody Glycoproteins Immune Response Immunotherapeutics Agenus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.2642 |
| 52 Week Low | 0.052 |
| Average Volume | 587,461 |
| 200-Day Moving Average | 0.32 |
| 50-Day Moving Average | 0.16 |
| 20-Day Moving Average | 0.08 |
| 10-Day Moving Average | 0.08 |
| Average True Range | 0.01 |
| RSI (14) | 42.86 |
| ADX | 30.63 |
| +DI | 15.35 |
| -DI | 21.12 |
| Chandelier Exit (Long, 3 ATRs) | 0.05 |
| Chandelier Exit (Short, 3 ATRs) | 0.11 |
| Upper Bollinger Bands | 0.09 |
| Lower Bollinger Band | 0.07 |
| Percent B (%b) | 0.89 |
| BandWidth | 21.29 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.0065 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.10 | ||||
| Resistance 3 (R3) | 0.10 | 0.10 | 0.10 | ||
| Resistance 2 (R2) | 0.10 | 0.09 | 0.10 | 0.10 | |
| Resistance 1 (R1) | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 |
| Pivot Point | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
| Support 1 (S1) | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 |
| Support 2 (S2) | 0.07 | 0.08 | 0.07 | 0.07 | |
| Support 3 (S3) | 0.07 | 0.07 | 0.07 | ||
| Support 4 (S4) | 0.07 |
